Life course health outcomes of children born to mothers with COVID-19
Maternal COVID-19 infection has resulted in elevated rates of preterm birth and low birth weight. According to a recent publication in JAMA Pediatrics, exposure to maternal COVID-19 infection may have broader implications on newborns later in life, suggesting a potential risk for long-term health outcomes among these individuals.
How effective are the Pfizer and the AstraZeneca vaccines against the delta variant?
In a recent study published in the New England Journal of Medicine, researchers from the UK have estimated the effectiveness of vaccination in preventing symptomatic disease caused by the delta or alpha variants.
Long-term analysis of COVID-19 patients demonstrates durable and broad immune responses against SARS-CoV-2
While scientists are striving to identify the specific protection mechanisms against SARS-CoV-2, a recent publication in Cell Reports Medicine followed a group of 254 COVID-19-recovered individuals who were infected during the first surge of COVID-19 in Seattle and Atlanta.
Growing evidence for safety and effectiveness of mix-and-match COVID-19 vaccination
Mixing COVID-19 vaccine products has been done to maximize the number of people that can be fully vaccinated in settings where vaccine availability is limited or unpredictable.
Forecasting the future of COVID-19
How will the global population continue to interact with the virus in the long-term? Articles in Nature and the Journal of the American Medical Association offer several scenarios, ranging from the complete eradication of the virus to the potential for ongoing severe infections, and to the evolution of the virus, among others.
Long Covid – Next Public Health Disaster on the Horizon
According to a recent New England Journal of Medicine article, more than 15 million cases of long COVID are expected in the United States alone.
Differences in immune response based on age after vaccination with the Pfizer vaccine
The mRNA-based Pfizer vaccine has demonstrated remarkable efficacy and is approved for use across a wide range of age groups from children aged 12 and up to the elderly.
Literature Review: effectiveness of the COVID-19 vaccines approved for use in Canada against circulating variants of concern
Variants of concern (VOCs) can potentially make COVID-19 vaccines less effective, both in terms of the immediate immune response and the durability of immunity.
Study in primates suggests that COVID vaccines in young children may be safe and effective
Immune responses to infections and vaccines may be different in children, compared to adults. A careful evaluation of novel vaccines in the pediatric population is therefore warranted.